Look it up on google. This company is rubbish and barely worth the office equipment and space it occupies in Cambridge. In situations like yesterday, Class Action Lawsuits and Dilution typically drive the final nail into the coffin before bankruptcy.
Dilution is next, meanwhile insiders cash out. Explains why no reputable institution is holding shares in this scam.
Your surgeon takes a tumor out. Sends it to hospital pathology lab. They send back a report. Oncologist makes a treatment decision based on studies, experience, trial and error. In comes FMI, your oncologist could send it to them, they analyze then using a huge database of information and gene profiling sends back a detailed report with best treatment regimens to maximize your odds of survival. Getting it right the first time also reduces cost. Called precision medicine. Buy all you can. This where medicine is heading.
What is their plan? Will they be issuing more shares to cover expenses? When will Cologuard start generating revenue? How many quarters before they run out of cash? Thanks.
Just posted this morning.
Just hit the wires.
Trying to decide?
NVAX will be bought the question is by who and for how much, and how soon.
Why wouldn't they? They may have a majority stake, but that doesn't preclude another interested party approaching FMI. Seems Roche has a specific interest in FMI that they'd like to protect.
Lead in results. My point is that the lead in results from Ignite 2 have such a wide margin of superiority over Levofloxacin, that it would seem impossible not to maintain that results into the Pivotal portion coming soon. Even if the pivotal portion results weren't as positive, I don't see 20 point superiority gap closing. So primary endpoint should be easy to obtain, and even the secondary endpoint looks promising.
70.8 vs 52.2 Responder Rate (Ervacycline vs Levofloxacin)
75.0 vs 56.5 Microbial Response (Ervacycline vs Levofloxacin)
That's a wide margin of superiority IMO. Particularly in a cUTI. Thoughts?